Skip to main content

Holiday schedule

Our Patient Service Centers will be closed on Wednesday, December 25, 2024 in observance of Christmas and Wednesday, January 1, 2025 in observance of New Year's Day. Have a healthy, happy holiday.

Hide
Quest Diagnostics

Oncology

A complete relationship from diagnosis to care

Advanced oncology diagnostics offer new ability to pinpoint types and locations of various cancers. And they can do so much more. Explore these 3 articles and a podcast by Quest experts to discover new ways oncology testing fits into the continuum of care—and helps lead to better patient outcomes.

Quest is your single-source solution with a comprehensive test menu; over 600 board-certified pathologists, dermatopathologists, and medical experts; leading technology; and committed customer service—delivering the experience of a boutique lab backed by the power of one of the largest labs in the world.

The role of advanced diagnostics in delivering better care

The FDA-approved Ki-67 MIB-1 pharmDx test is the sole companion diagnostic for VERZENIO TM, a 2017-approved oral, solid dose medication for advanced or metastatic HR-positive, HER2-negative breast cancer. The test assesses Ki-67 proliferation to evaluate whether a patient’s tumor may respond to VERZENIO in the early, node-positive breast cancer indication. Learn how it-and tests like it- are making it easier to know whether patients will respond to treatment.
Read "The importance of using an FDA approved companion diagnostic"
The doctor reads procedure preparation instructions to her adult female patient.
Currently, an acute myeloid leukemia diagnosis is considered a medical emergency. But new research suggests waiting for more detailed genetic testing may be beneficial to the outcome. Learn how—and why—the approach is changing.
Read "Balancing the desire for quick AML results with precision genetic testing"
An image of molecular testing results
Since discovering cancer early is key to better outcomes, advanced diagnostics that can screen for multiple cancer biomarkers at once are extremely valuable. Learn how liquid biopsies are improving early diagnosis across patient and cancer types at low cost.
Read "4 critical steps to optimize cancer diagnosis"
2 laboratory professionals organizing test tubes
A streamlined clinical pathway offers the best chance for high-quality care—and helps newly diagnosed patients feel more at ease. Discover how advanced diagnostics help create the pathways that lead to better outcomes.
Listen to Dr Yuri Fesko in the podcast "Optimize Oncology Care with Clinical Pathways"
An image of a doctor speaking with two patients.

Quest offers its clients a dedicated oncology customer support line to assist with any test-related questions: 1.833.773.1441

Quest Advanced Oncology offers a powerful and comprehensive portfolio of testing that spans the full continuum of cancer care. Quest delivers the resources you need to help make advanced cancer diagnostics more accessible, actionable, and affordable.

About 1 in 3 people in the United States will develop cancer during their lifetime,1 so it’s not uncommon to have many cancers in the same family. Less often, cancers in a family are strongly linked to an inherited gene mutation that is part of a hereditary cancer syndrome.  

Our hereditary cancer solutions help close the gap between the unknown and the path forward. A complete portfolio of hereditary cancer tests, services, and expert analysis from our on-staff genetic counselors help you understand your patients’ risk and are the first step in our approach to supporting a patient’s cancer journey.

Tests include:

  • Comprehensive and guideline-based hereditary cancer panels
  • Cancer-specific panels
  • Hereditary cancer syndrome panels
  • Single-gene and single-site tests

Our genetic counselors are available to consult about test selection and results interpretation. To speak with a genetic counselor, call 1.866.GENE.INFO (1.866.436.3463).

Learn more about our hereditary cancer screening solutions.

 

Supporting excellence in cancer care through precision medicine solutions

Quest Diagnostics offers decision-support tools to help physicians develop a treatment plan for navigating the standard of care and clinical trial options, and beyond. We offer a holistic view of the patient tumor with our Solid Tumor Expanded Panel, a guideline-driven solution for actionable and emerging biomarkers with our Solid Tumor Core Panel and disease-specific panels for prognosis and treatment decisions.

Our solid tumor solutions include such cancer types as:

⦁    Breast
⦁    Cervical
⦁    GI, Colorectal
⦁    Lung
⦁    Melanoma
⦁    Prostate
⦁    Thyroid

Learn more about our pan-cancer solid tumor solutions

Contact us

Want to discover new ways oncology testing helps lead to better patient outcomes? Get in touch today.

559

* indicates required

About our tests

Visit our ThoughtLab for hospitals and health systems resources

Pathology & Laboratory Medicine
Article
4 critical steps to optimize cancer diagnosis
Pathology & Laboratory Medicine
Article
Balancing the desire for quick AML results with precision genetic testing
Pathology & Laboratory Medicine
Article
The importance of using an FDA approved companion diagnostic
News & Trends
Publication
Cancer diagnoses still lag, 2 years into the pandemic
View All Articles

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA-certified laboratories that provide HIPAA-covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA-covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2024 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.